GSK Handed $106M Verdict For Paxil Generic Contract Breach

Law360, New York (March 26, 2014, 5:57 PM EDT) -- A New Jersey federal jury on Tuesday slapped GlaxoSmithKline LLC with a $106.7 million verdict for allegedly breaching an exclusive contract with Mylan Inc. by allowing Apotex Inc. to sell generic versions of its antidepressant Paxil as part of an antitrust settlement.

Following a nine-day trial, the jury found that GSK breached a 2007 agreement granting Mylan an exclusive right to market and sell paroxetine hydrochloride, the generic name for Paxil, when it allowed Apotex to sell generics of the drug in 2010.

The jury found...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.